BioDelivery Sciences Soars on Positive Trial Data (BDSI)

Shares of BioDelivery Sciences International (BDSI) soared 22% in active premarket trade after the company and its partner, Endo Pharmaceuticals, said a late-stage trial of its severe pain treatment met its primary efficacy endpoint.

At 10:30 AM the stock is up 15.51 % form Fridays close to $13.87 and touched a new high briefly at $14.38. Volume is high with 3.5 million shared trading hands. Normal volume is 726K shares per day.

BioDelivery Sciences International, Inc., (BDSI) a specialty pharmaceutical company, develops and commercializes therapeutics in the areas of pain management and oncology supportive care.

BioDelivery (BDSI) showed that its drug called Bema buprenorphine, which being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, successfully met its primary efficacy endpoint in demonstrating that the drug resulted in “significantly improved chronic pain relief compared to placebo,” according to the trial results.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.